Drug intelligence / Profile preview

NT1

Development stage: Preclinical
Lead developer: Neurotez
Modality: Peptides
Administration: Intravenous, Oral

Overview

NT1 is a small peptide drug candidate developed by Neurotez, Inc., specifically designed for the treatment and prevention of early-onset familial Alzheimer's disease (FAD). The therapeutic mechanism involves disrupting the abnormal interaction between presenilin 1 (PS1) and cytoplasmic linker protein 170 (CLIP-170). In familial AD, this interaction is linked to increased production of amyloid-beta peptides. By blocking this protein-protein interaction, NT1 aims to reduce amyloid-beta levels and potentially serve as a preventative therapy for individuals carrying FAD-associated mutations.

Targets

PSEN1 (Presenilin 1)CLIP1 (CAP-Gly domain-containing linker protein 1)

Beyond the preview

Go deeper on NT1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NT1.

Explore the full profile